MX2010002210A - Derivados de catecolamina y profarmacos de los mismos. - Google Patents

Derivados de catecolamina y profarmacos de los mismos.

Info

Publication number
MX2010002210A
MX2010002210A MX2010002210A MX2010002210A MX2010002210A MX 2010002210 A MX2010002210 A MX 2010002210A MX 2010002210 A MX2010002210 A MX 2010002210A MX 2010002210 A MX2010002210 A MX 2010002210A MX 2010002210 A MX2010002210 A MX 2010002210A
Authority
MX
Mexico
Prior art keywords
prodrugs
catecholamine derivatives
derivatives
catecholamine
therapy
Prior art date
Application number
MX2010002210A
Other languages
English (en)
Inventor
Benny Bang-Andersen
Ask Pueschl
Morten Joergensen
Niels Moerk
Jennifer Larsen
Haakan Vilhelm Wikstroem
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39877715&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2010002210(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of MX2010002210A publication Critical patent/MX2010002210A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/06—Ring systems of three rings
    • C07D221/08—Aza-anthracenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/12—Antiepileptics; Anticonvulsants for grand-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/58—[b]- or [c]-condensed
    • C07D209/60—Naphtho [b] pyrroles; Hydrogenated naphtho [b] pyrroles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Portable Nailing Machines And Staplers (AREA)
  • Indole Compounds (AREA)

Abstract

La presente invención se refiere a nuevos derivados de catecolamina de la Fórmula (I), a procedimientos para su preparación, a composiciones farmacéuticas que los contienen y a su uso en terapia.
MX2010002210A 2007-08-31 2008-08-28 Derivados de catecolamina y profarmacos de los mismos. MX2010002210A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200701250 2007-08-31
PCT/DK2008/050215 WO2009026935A1 (en) 2007-08-31 2008-08-28 Catecholamine derivatives and prodrugs thereof

Publications (1)

Publication Number Publication Date
MX2010002210A true MX2010002210A (es) 2010-03-17

Family

ID=39877715

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010002210A MX2010002210A (es) 2007-08-31 2008-08-28 Derivados de catecolamina y profarmacos de los mismos.

Country Status (29)

Country Link
EP (4) EP2197883B1 (es)
JP (4) JP5548125B2 (es)
KR (3) KR20150115963A (es)
CN (3) CN101687878A (es)
AR (2) AR068044A1 (es)
AU (2) AU2008291426B2 (es)
BR (2) BRPI0815894A2 (es)
CA (2) CA2697688A1 (es)
CL (2) CL2008002564A1 (es)
CO (2) CO6270232A2 (es)
CY (1) CY1117326T1 (es)
DK (1) DK2197883T3 (es)
EA (2) EA018413B1 (es)
ES (1) ES2557485T3 (es)
HR (1) HRP20151334T1 (es)
HU (1) HUE025882T2 (es)
IL (1) IL203080A (es)
MX (1) MX2010002210A (es)
MY (2) MY148948A (es)
NZ (2) NZ583551A (es)
PL (1) PL2197883T3 (es)
PT (1) PT2197883E (es)
RS (1) RS54470B1 (es)
SG (1) SG184711A1 (es)
SI (1) SI2197883T1 (es)
TW (2) TWI404702B (es)
UA (2) UA98804C2 (es)
WO (2) WO2009026935A1 (es)
ZA (2) ZA200909191B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI404702B (zh) * 2007-08-31 2013-08-11 Lundbeck & Co As H 兒茶酚胺衍生物和其前藥
US8067410B2 (en) 2008-06-27 2011-11-29 H. Lundbeck A/S Phenolic and catecholic amines and prodrugs thereof
EP2303851A1 (en) * 2008-06-27 2011-04-06 H. Lundbeck A/S Novel phenolic and catecholic amines and prodrugs thereof
TW201036949A (en) * 2009-02-27 2010-10-16 Lundbeck & Co As H Treatment of dyskinesia related disorders
TW201035054A (en) * 2009-02-27 2010-10-01 Lundbeck & Co As H Methods of administering (4aR, 10aR)-1-n-propyl-1,2,3,4,4a,5,10,10a-octahydro-benzo[g]quinoline-6,7-diol and pharmaceutical compositions thereof
JOP20200114A1 (ar) 2017-11-24 2020-05-17 H Lundbeck As عقاقير أولية جديدة من الكاتيكولامين للاستخدام في علاج مرض باركنسون
WO2020070099A1 (en) 2018-10-02 2020-04-09 H. Lundbeck A/S Administration of catecholamine prodrugs in combination with a 5-ht2b antagonist
US11168056B2 (en) * 2019-05-20 2021-11-09 H. Lundbeck A/S Process for the manufacturing of (6aR,10aR)-7-propyl-6,6a,7,8,9,10,10a,11-octahydro-[1,3]dioxolo[4′,5′:5,6]benzo[1,2-G]quinoline and (4aR,10aR)-1-propyl-1,2,3,4,4a,5,10,10a-octahydro-benzo[G]quinoline-6,7-diol
US11111263B2 (en) 2019-05-20 2021-09-07 H. Lundbeck A/S Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
US11104697B2 (en) * 2019-05-20 2021-08-31 H. Lundbeck A/S Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4AR,10AR)-7-hydroxy-1- propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
US11130775B2 (en) * 2019-05-20 2021-09-28 H. Lundbeck A/S Solid forms of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
EP3972971A1 (en) * 2019-05-21 2022-03-30 H. Lundbeck A/S New catecholamine prodrugs for use in the treatment of parkinson's diseases
EP3972600A1 (en) 2019-05-21 2022-03-30 H. Lundbeck A/S Catecholamine carbamate prodrugs for use in the treatment of parkinson s disease
US20220220077A1 (en) * 2019-05-21 2022-07-14 H. Lundbeck A/S New catecholamine prodrugs for use in the treatment of parkinson's disease
JP2022533913A (ja) 2019-05-21 2022-07-27 ハー・ルンドベック・アクチエゼルスカベット パーキンソン病の治療に使用するための新規なカテコールアミンプロドラッグ
CN114478298A (zh) * 2020-11-12 2022-05-13 成都西岭源药业有限公司 一种造影剂碘佛醇的纯化方法
EP4247793A1 (en) 2020-11-17 2023-09-27 H. Lundbeck A/S New catecholamine prodrugs for use in the treatment of parkinson's disease
CN113620760A (zh) * 2021-09-07 2021-11-09 张家口思睿凯科技有限公司 一种电子盐反应液和不饱和芳香烃类化合物的还原方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4080456A (en) * 1971-10-26 1978-03-21 Schering Aktiengesellschaft Diacylapomorphines
CH648300A5 (en) * 1979-06-22 1985-03-15 Sandoz Ag Phenanthrene derivatives and medicaments containing them
US4543256A (en) * 1982-03-17 1985-09-24 Northeastern University (-)-10,1L Methylenedioxy-N-N-propylnoraporphine and methods employing it for inhibiting the effects of epileptic seizures and for prevention and treatment of duodenal ulcers
WO1990012574A1 (en) * 1989-04-25 1990-11-01 Northeastern University Dopamine agonist compounds
PT95142B (pt) * 1989-08-30 1997-05-28 Sankyo Co Processo para a preparacao de derivados indolobenzoquinolinicos com accao anti-arritmica
TW357143B (en) * 1995-07-07 1999-05-01 Novartis Ag Benzo[g]quinoline derivatives
WO1997017326A1 (en) * 1995-11-10 1997-05-15 Novo Nordisk A/S Enantiomers of cis-benz[e]indole compounds, their preparation and utility as dopamine-d3 receptor selective agents
CN1241998A (zh) * 1996-10-30 2000-01-19 伊莱利利公司 苯并[f]喹啉酮的合成
SE0002934D0 (sv) * 2000-08-17 2000-08-17 Axon Biochemicals Bv New aporphine esters and in their use in therapy
SE0102036D0 (sv) 2001-06-08 2001-06-08 Axon Biochemicals Bv Pharmaceutical formulation for the efficient administration of apomorphine, 6aR- (-) -N- Propyl- norapomorphine and their derivatives and pro-drugs thereof
AR030357A1 (es) * 2000-08-18 2003-08-20 Lundbeck & Co As H Derivados 4 -, 5 -, 6 - y 7-indol
US20050090518A1 (en) * 2003-10-24 2005-04-28 Nastech Pharmaceutical Company Inc. Method for treating parkinson's disease using apomorphine and apomorphine prodrugs
TWI404702B (zh) * 2007-08-31 2013-08-11 Lundbeck & Co As H 兒茶酚胺衍生物和其前藥

Also Published As

Publication number Publication date
HUE025882T2 (en) 2016-04-28
JP2014111635A (ja) 2014-06-19
AR068044A1 (es) 2009-10-28
BRPI0815894A2 (pt) 2015-02-24
NZ583551A (en) 2012-07-27
EA200971107A1 (ru) 2010-06-30
CL2008002564A1 (es) 2009-07-17
EP2197883A1 (en) 2010-06-23
TW200914426A (en) 2009-04-01
AU2008291425A1 (en) 2009-03-05
SG184711A1 (en) 2012-10-30
HRP20151334T1 (hr) 2016-01-01
RS54470B1 (en) 2016-06-30
KR20100051834A (ko) 2010-05-18
PL2197883T3 (pl) 2016-03-31
WO2009026935A1 (en) 2009-03-05
AU2008291426A1 (en) 2009-03-05
ZA200909191B (en) 2011-03-30
JP5548125B2 (ja) 2014-07-16
BRPI0813456A2 (pt) 2014-12-23
KR20150115963A (ko) 2015-10-14
EP2195291A1 (en) 2010-06-16
AR068045A1 (es) 2009-10-28
EP2662358A1 (en) 2013-11-13
CA2697688A1 (en) 2009-03-05
TWI404702B (zh) 2013-08-11
UA97989C2 (uk) 2012-04-10
KR20100046111A (ko) 2010-05-06
EP2197883B1 (en) 2015-11-18
CO6270232A2 (es) 2011-04-20
NZ582379A (en) 2011-08-26
EA018011B1 (ru) 2013-04-30
JP2010536890A (ja) 2010-12-02
WO2009026934A1 (en) 2009-03-05
ZA201001422B (en) 2011-06-29
CN101842354A (zh) 2010-09-22
CA2691961C (en) 2013-12-17
TW200911752A (en) 2009-03-16
CN101687878A (zh) 2010-03-31
JP2010536889A (ja) 2010-12-02
UA98804C2 (ru) 2012-06-25
CL2008002558A1 (es) 2009-08-07
CY1117326T1 (el) 2017-04-26
AU2008291426B2 (en) 2013-01-31
KR101597367B1 (ko) 2016-02-24
CN107253956A (zh) 2017-10-17
JP5802792B2 (ja) 2015-11-04
EP3009437A1 (en) 2016-04-20
CO6260082A2 (es) 2011-03-22
SI2197883T1 (sl) 2016-01-29
AU2008291425B2 (en) 2012-12-06
DK2197883T3 (en) 2016-01-11
EA201070327A1 (ru) 2010-08-30
ES2557485T3 (es) 2016-01-26
IL203080A (en) 2014-11-30
CA2691961A1 (en) 2009-03-05
EA018413B1 (ru) 2013-07-30
PT2197883E (pt) 2016-02-02
MY179527A (en) 2020-11-10
JP2014148528A (ja) 2014-08-21
MY148948A (en) 2013-06-14

Similar Documents

Publication Publication Date Title
MX2010002210A (es) Derivados de catecolamina y profarmacos de los mismos.
MX2011011661A (es) Compuestos 1-cianoetilheterociclilcarboxamida sustituidos 750.
MY153258A (en) Pyrazinone derivatives and their use inthe threatment of lung diseases
HK1138840A1 (en) Azabiphenylaminobenzoic acid derivatives as dhodh inhibitors
PH12015501385A1 (en) Autotaxin inhibitors
MY159630A (en) Pharmaceutical composition comprising linagliptin and optionally a sglt2 inhibitor, and uses thereof
MY149731A (en) Compounds
UA95644C2 (ru) Пиридазиноновые производные, фармацевтическая композиция и способ лечения заболеваний
MX2010009022A (es) Derivados 16 alfa, 17 alfa-acetal glucocorticoesteroideos y su uso.
MX2009010059A (es) Derivados de quinolina para el tratamiento de enfermedades inflamatorias.
GEP20146125B (en) Aminopyrimidines as syk inhibitors
MX2011008634A (es) Derivados de aminotetralina composiciones farmaceuticas que los contienen y su uso en terapia.
PH12014501514A1 (en) New azetidine derivatives, pharmaceutical compositions and uses thereof
TW200745084A (en) Novel compounds
TW200738659A (en) Novel compounds
TW200745122A (en) New compounds I
JO2682B1 (en) Derivatives of alkynil-8.1-naphthayridone, preparations thereof and therapeutic use thereof
MX2010013682A (es) Derivados de 2,4-diamino-l,3,5-triazina triciclicos utiles para el tratamiento del cancer y trastornos mieloproliferativos.
TW200738627A (en) Trialkylsilyl-indoles
EA201001747A1 (ru) Бензоксазиноновые производные, действующие в качестве агониста бета-2-адренорецептора, для лечения респираторных расстройств
IN2012DN01292A (es)
TW200745133A (en) New compounds II
MX2009010225A (es) Nuevos compuestos 707 y sus usos.
TW200738611A (en) 9-Chloro-15-deoxyprostaglandin derivatives, process for their preparation and their use as medicaments
IL191670A0 (en) Compounds for the inhibition of apoptosis

Legal Events

Date Code Title Description
FG Grant or registration